None of the 29 investors followed here reported a position in ATXI in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ATXI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jan 1, 2026 | Fortress Biotech, Inc.Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 0.00 per share. | 111.2K | — |
| Mar 30, 2025 | Fortress Biotech, Inc.Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 0.00 per share. | 33.7K | — |
| Dec 1, 2024 | Herskowitz NeilDirector | Sale at price 2.00 per share. | 23 | $46 |
| Nov 4, 2024 | Kranzler Jay DDirector | Sale at price 2.24 per share. | 61 | $137 |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -70.3 | -5.9 | 52.6 | 89.7 | -45.5 | -6.7 | 38.5 | 16.6 | -11.5 | 0.1 | −41.1% | ||
| 2025 | -32.0 | -19.1 | -72.7 | -19.7 | -9.5 | -7.9 | 126.7 | 25.3 | 38.0 | -8.5 | 6.2 | -11.0 | −66.0% |
| 2024 | -8.1 | 2.5 | -2.8 | -54.7 | -31.3 | 1.7 | -20.0 | -9.3 | -2.0 | -3.6 | -10.6 | -6.8 | −83.4% |
| 2023 | 19.0 | -19.6 | 5.0 | -18.5 | 14.2 | 7.8 | -10.3 | -26.1 | -8.9 | -66.8 | -9.8 | -24.1 | −86.1% |
| 2022 | -19.5 | -53.5 | 41.7 | -23.2 | -24.3 | -3.8 | -4.8 | -6.1 | 179.1 | -76.3 | -43.9 | -13.4 | −91.5% |
| 2021 | -0.5 | -20.6 | 29.1 | -15.7 | -3.1 | -49.4 | -28.7 | 1.1 | -17.7 | 6.0 | -10.8 | -35.6 | −84.7% |
| 2020 | 2.0 | -9.3 | 0.7 | 6.3 | 20.7 | -6.1 | -5.9 | 9.9 | -2.7 | -71.0 | 8.0 | 75.5 | −38.0% |
| 2019 | 12.8 | -8.9 | -14.4 | 3.8 | 5.5 | 21.2 | -5.6 | 5.9 | -5.4 | -3.9 | 3.0 | 62.7 | +77.8% |
| 2018 | 4.1 | 35.5 | -11.7 | -16.0 | 6.9 | -11.6 | 10.3 | -9.1 | -21.4 | 25.2 | 47.6 | 3.6 | +49.2% |
| 2017 | -16.0 | -12.4 | -5.6 | -3.8 | -21.8 | -13.0 | −54.5% |
No analyst coverage for this instrument.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
No recent headlines.